drugset / Trial / NCT05238727

Volume Increase Versus Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success

NCT05238727

Unknown 75 enrolled Cairo University
RandomizedParallel-groupDouble-blindPrevention

Summary

To assess the anesthetic success of inferior alveolar nerve block (IANB), intraoperative pain intensity and need for supplemental anesthesia on administration of 1.8ml or 3.6ml 2% mepivacaine IANB, or 1.8ml 2% mepivacaine IANB plus 1.8ml 4% articaine buccal infiltration (BI) in mandibular molars with symptomatic irreversible pulpitis.

Timeline

Start
2022-03
Primary completion
2023-03
Completion
2023-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Articaine Other / unclassified 1.8 ml Other
Comparator Mepivacaine Other / unclassified 1.8 ml Other
Comparator Mepivacaine Other / unclassified 3.6 ml Other

Indications